BTK and diffuse large B-cell lymphoma: A recent study on DLBCL patients17 suggests that TNFAIP3 inactivation negatively impacts therapeutic responses to ibrutinib, a BTK inhibitor known to inhibit B-cell receptor and NF-κB signaling26,27.